Suspension of trading

Highlights Akoya Biosciences, Inc.

Stocks

AKYA

US00974H1041

Advanced Medical Equipment & Technology

Delayed Nasdaq Other stock markets 04:00:00 2025-07-07 pm EDT			5-day change	1st Jan Change
1.290 ^USD	-5.15%		-.--%	-

Mar. 02	Acrivon Therapeutics, Inc. and Akoya Biosciences Enter into Termination and Transition Agreement	CI
25-07-18	Quanterix terminates executives of Akoya Biosciences	RE

Highlights

25-07-08	Quanterix and Akoya Biosciences Announces Executive and Board Changes	CI
25-05-21	An undisclosed buyer agreed to acquire Akoya Biosciences, Inc..	CI
25-05-21	Akoya Biosciences Receives Unsolicited Buyout Offer From Third Party	MT
25-05-12	Earnings Flash (AKYA) Akoya Biosciences Reports Q1 Revenue $16.6M, vs. FactSet Est of $19.2M	MT
25-05-12	Akoya Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-24	Akoya Biosciences, Inc. and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas	CI
25-04-24	Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-World IO60 Insights At AACR 2025	CI
25-04-23	Akoya Biosciences and Singapore Translational Cancer Consortium Partner on Super Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore	CI
25-04-02	Akoya Biosciences and Team SAMBAI Announce Selection of the Phenocycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities	CI
25-03-24	Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences	RE
25-03-17	Akoya Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-05	Akoya Biosciences, Inc. Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels	CI
25-01-13	Canaccord Genuity Downgrades Akoya Biosciences to Hold From Buy, $3.50 Price Target	MT
25-01-09	Quanterix Corporation entered into an agreement to acquire Akoya Biosciences, Inc. from Telegraph Hill Partners III, L.P, a fund managed by Telegraph Hill Partners, PSC Capital Partners LLC, aMoon Growth Fund II, L.P., a fund managed by aMoon Fund and others for $190 million.	CI
24-12-10	Akoya Biosciences Secures Exclusive License for NeraCare's Immunoprint Test	MT
24-12-10	Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions	CI
24-11-14	Earnings Flash (AKYA) AKOYA BIOSCIENCES Reports Q3 Revenue $18.8M	MT
24-11-14	Akoya Biosciences, Inc. Revises Earnings Guidance for the Full Year 2024	CI
24-11-14	Akoya Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-11-06	Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler-Fusion 2.0 System and the new Phenocode Discovery IO60 Panel from Akoya Biosciences	CI
24-10-07	Akoya Biosciences Spatial Proteomics Platform to be Used in Cancer Immunotherapy Consortium	MT
24-10-07	Akoya's Leading Spatial Proteomics Platforms Selected for Use by Uk-Based Manifest Consortium to Revolutionize Cancer Immunotherapy	CI
24-08-05	Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q2 Revenue $23.2M, vs. Street Est of $23.6M	MT
24-08-05	Akoya Biosciences, Inc. Updates Earnings Guidance for the Full Year of 2024	CI
24-08-05	Akoya Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI